First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

被引：0
|
作者：
Andre, Thierry
Elez, Elena
Lenz, Heinz-Josef
Jensen, Lars Henrik
Touchefeu, Yann
Van Cutsem, Eric
Garcia-Carbonero, Rocio
Tougeron, David
Mendez, Guillermo
Schenker, Michael
de la Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Aubin, Francine
Cela, Elvis
Chen, Tian
Lei, Ming
Jin, Lixian
Lonardi, Sara
机构：
[1] Sorbonne Univ, Paris, France
[2] Hop St Antoine, Assistance Publ Hop Paris, Paris, France
[3] Vall Hebron Univ Hosp, Barcelona, Spain
[4] Inst Oncol VHIO, Barcelona, Spain
[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Univ Hosp Southern Denmark, Vejle Hosp, Vejle, Denmark
[7] Ctr Hosp Univ Nantes, Nantes, France
[8] Univ Penn, Philadelphia, PA USA
[9] UCM, Hosp Univ 12 Octubre Imas12, Madrid, Spain
[10] Ctr Hosp Univ Poitiers Site Miletrie, Poitiers, France
[11] Hosp Univ Fdn Favaloro, Buenos Aires, Argentina
[12] Centrul Oncol Sf Nectarie, Craiova, Romania
[13] Univ Med & Pharm, Craiova, Romania
[14] Ctr Leon Berard, Lyon, France
[15] Hosp Univ Virgendel Rocio, Seville, Spain
[16] Natl Canc Ctr Hosp East Kashiwa, Chiba, Japan
[17] Shanghai East Hosp, Shanghai, Peoples R China
[18] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[19] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.LBA143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA143
引用
收藏
页码：LBA143 / LBA143
页数：1
相关论文
共 50 条
  • [41] PEMBROLIZUMAB MONOTHERAPY FOR MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) RECURRENT GLIOMAS: RESULTS FROM THE MULTICOHORT PHASE 2 KEYNOTE-158 STUDY
    Baldini, Capucine
    Cassier, Philippe A.
    Delord, Jean-Pierre
    Simonelli, Matteo
    Touat, Mehdi
    Yao, Lili
    Duic, J. Paul
    Gozman, Alexander
    Marabelle, Aurelien
    NEURO-ONCOLOGY, 2022, 24 : 59 - 60
  • [42] Evaluating the patient-level association between progression-free survival and overall survival in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC) treated with immune checkpoint inhibitors
    Roodhart, J. M. L.
    Sharpe, D. J.
    Tate, A. E.
    Bertwistle, D.
    Dixon, M.
    Chen, H-H.
    Kurt, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S27 - S27
  • [43] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Shiu, K. K.
    Andre, T.
    Kim, T. W.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    De la Fouchardiere, C.
    Rivera, F.
    Fernandez, M. E. Elez
    Le, D. T.
    Yoshino, T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1271 - S1272
  • [45] Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab ± ipilimumab: CheckMate 142
    Kopetz, Scott
    Zagonel, Vittorina
    Overman, Michael J.
    McDermott, Ray
    Morse, Michael A.
    Chen, Franklin L.
    Lee, James
    Moss, Rebecca A.
    Ling, Lilan
    Greenfield, Alexander
    Greenawalt, Danielle
    Cao, Z. Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [46] Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.
    Diaz, Luis A.
    Le, Dung T.
    Yoshino, Takayuki
    Andre, Thierry
    Bendell, Johanna C.
    Koshiji, Minori
    Zhang, Yinghua
    Kang, S. Peter
    Lam, Bao
    Jaeger, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
    Andre, T.
    Lonardi, S.
    Wong, K. Y. M.
    Lenz, H. -J
    Gelsomino, F.
    Aglietta, M.
    Van Cutsem, E.
    McDermott, R.
    Hill, A.
    Sawyer, M. B.
    Hendlisz, A.
    Neyns, B.
    Abdullaev, S.
    Memaj, A.
    Lei, M.
    Dixon, M.
    Kopetz, S.
    Overman, M. J.
    Morse, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 1052 - 1060
  • [48] Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
    Andre, Thierry
    Elez, Elena
    Lenz, Heinz-Josef
    Jensen, Lars Henrik
    Touchefeu, Yann
    Van Cutsem, Eric
    Garcia-Carbonero, Rocio
    Tougeron, David
    Mendez, Guillermo Ariel
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Mozo, Jose Luis Manzano
    Dahan, Laetitia
    Tortora, Giampaolo
    Chalabi, Myriam
    Goekkurt, Eray
    Braghiroli, Maria Ignez
    Joshi, Rohit
    Cil, Timucin
    Aubin, Francine
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Jin, Lixian
    Blum, Steven, I
    Lonardi, Sara
    LANCET, 2025, 405 (10476): : 383 - 395
  • [49] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
    Cohen, Romain
    Bennouna, Jaafar
    Meurisse, Aurelia
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Vernerey, Dewi
    Menu, Yves
    Andre, Thierry
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [50] Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
    Overman, M. J.
    Kopetz, S.
    Lonardi, S.
    McDermott, R.
    Leone, F.
    Leach, J.
    Lenz, H-J.
    Hendlisz, A.
    Morse, M.
    Garcia-Alfonso, P.
    Desai, J.
    Hill, A.
    Moss, R. A.
    Goldberg, M. V.
    Lin, C-S.
    Tang, H.
    Andre, T.
    ANNALS OF ONCOLOGY, 2016, 27
12345